- Home
- SGC vs CBIO Comparison
SGC vs CBIO Comparison
Compare SGC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- CBIO
- Stock Information
- Founded
- SGC 1920
- CBIO 2003
- Country
- SGC United States
- CBIO United States
- Employees
- SGC N/A
- CBIO N/A
- Industry
- SGC Apparel
- CBIO
- Sector
- SGC Consumer Discretionary
- CBIO
- Exchange
- SGC Nasdaq
- CBIO Nasdaq
- Market Cap
- SGC 215.7M
- CBIO 173.5M
- IPO Year
- SGC N/A
- CBIO N/A
- Fundamental
- Price
- SGC $9.95
- CBIO $13.00
- Analyst Decision
- SGC Strong Buy
- CBIO Strong Buy
- Analyst Count
- SGC 3
- CBIO 5
- Target Price
- SGC $17.33
- CBIO $25.60
- AVG Volume (30 Days)
- SGC 30.5K
- CBIO 120.8K
- Earning Date
- SGC 11-03-2025
- CBIO 11-23-2025
- Dividend Yield
- SGC 5.63%
- CBIO N/A
- EPS Growth
- SGC N/A
- CBIO N/A
- EPS
- SGC 0.52
- CBIO N/A
- Revenue
- SGC $576,240,000.00
- CBIO N/A
- Revenue This Year
- SGC $1.76
- CBIO N/A
- Revenue Next Year
- SGC $3.37
- CBIO N/A
- P/E Ratio
- SGC $19.07
- CBIO N/A
- Revenue Growth
- SGC 4.03
- CBIO N/A
- 52 Week Low
- SGC $9.11
- CBIO $9.81
- 52 Week High
- SGC $18.48
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- SGC 36.79
- CBIO 57.15
- Support Level
- SGC $9.76
- CBIO $11.96
- Resistance Level
- SGC $10.51
- CBIO $13.20
- Average True Range (ATR)
- SGC 0.35
- CBIO 0.89
- MACD
- SGC 0.04
- CBIO 0.21
- Stochastic Oscillator
- SGC 25.33
- CBIO 94.10
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.